Research
Hormonal
GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors are preferred first-line treatments for patients with Type 2 Diabetes and obesity or cardiovascular disease, respectively, due to their weight-reducing and cardioprotective properties.
If you have Type 2 Diabetes and obesity or heart disease, ask your doctor about GLP-1 receptor agonists or SGLT2 inhibitors. These drugs not only help control blood sugar but also promote weight loss and protect your heart, making them preferred choices over metformin alone for many patients.
ModerateSupportsMEDIUM confidence
The choice of these treatments also matches with the main factors considered when selecting the most appropriate therapy. For example, more weight- reducing treatments were used in profile 2, which presented with obesity, than in profile 1, which presented with overweight. The survey showed that GLP- 1 RA were preferred for a profile with obesity but without CVD (profile 2); however, in people with established CVD (profile 3), the triple combination of metformin, SGLT2i and GLP- 1 RA was the most selected therapy.
Why this rating
Based on physician survey responses and cited guidelines.
Source
Insights Into the Management of Type 2 Diabetes at Diagnosis in Spain: The <scp>NEW2TYPE2</scp> Study
Concha F. García‐Prieto et al. · Endocrinology Diabetes & Metabolism · 2025
DOI 10.1002/edm2.70095
cross_sectional · n=105
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Early intensive intervention targeting stringent glycaemic control (HbA1c ≤ 6.5%) and significant weight loss (≥10%) at diagnosis improves long-term prognosis and prevents microvascular complications in younger patients with longer life expectancy.Moderate
- Weight loss of 10-15% in patients with obesity and Type 2 Diabetes has disease-modifying effects, including improved glycaemic control, reduced need for medication, and potential disease remission.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →